This compound is hydrophilic rather than lipophilic and demonstrates low cell permeability. Please see the link below to review a publication that may be of interest:
https://pubmed.ncbi.nlm.nih.gov/7955780/#:~:text=The%20hydrophilic%20nature%20of%20pravastatin,cross%20the%20blood%2Dbrain%20barrier.
P4498
Pravastatin sodium salt hydrate
synthetic (organic), ≥98% (HPLC), HMG-CoA reductase inhibitor, powder
Synonym(s):
(βR, δR,1S,2S,6S,8S,8aR)-1,2,6,7,8,8a-Hexahydro-β, δ,6-trihydroxy-2-methyl-8[(2S)-2-methyl-1-oxobutoxyl]-1-naphthaleneheptanoic acid sodium hydrate, Eptastatin sodium salt hydrate
Sign In to View Organizational & Contract Pricing.
Select a Size
Change View
| Size/SKU | Availability | Price |
|---|---|---|
25 mg | Please contact Customer Service for Availability | 2 310,00 CZK |
About This Item
Empirical Formula (Hill Notation):
C23H35O7Na · xH2O
CAS Number:
Molecular Weight:
446.51 (anhydrous basis)
UNSPSC Code:
12352200
PubChem Substance ID:
NACRES:
NA.77
MDL number:
Assay:
≥98% (HPLC)
Form:
powder
Product Name
Pravastatin sodium salt hydrate, ≥98% (HPLC), powder
biological source
synthetic (organic)
Quality Segment
assay
≥98% (HPLC)
form
powder
color
white
mp
171.2-173 °C
solubility
H2O: >10 mg/mL
originator
Bristol-Myers Squibb
storage temp.
2-8°C
SMILES string
[Na+].[H][C@@](O)(CC[C@H]1[C@@H](C)C=CC2=C[C@@H](O)C[C@H](OC(=O)[C@@H](C)CC)[C@]12[H])C[C@@H](O)CC([O-])=O
InChI
1S/C23H36O7.Na/c1-4-13(2)23(29)30-20-11-17(25)9-15-6-5-14(3)19(22(15)20)8-7-16(24)10-18(26)12-21(27)28;/h5-6,9,13-14,16-20,22,24-26H,4,7-8,10-12H2,1-3H3,(H,27,28);/q;+1/p-1/t13-,14-,16+,17+,18+,19-,20-,22-;/m0./s1
InChI key
VWBQYTRBTXKKOG-IYNICTALSA-M
Gene Information
human ... HMGCR(3156)
General description
Application
Biochem/physiol Actions
Pravastatin sodium is a competitive, water-soluble 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor.
Competitive, water-soluble 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor. Inhibits cholesterol synthesis in vivo (Ki ~1 nM).
Features and Benefits
This compound was developed by Bristol-Myers Squibb. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.
1 of 1
This Item | |||
|---|---|---|---|
| description ≥98% (HPLC), powder | description A water-soluble, competitive 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor that potently blocks in vivo cholesterol synthesis (Ki = ~1 nM). | description United States Pharmacopeia (USP) Reference Standard | description United States Pharmacopeia (USP) Reference Standard |
| form powder | form crystalline solid | form - | form - |
| assay ≥98% (HPLC) | assay ≥98% (HPLC) | assay - | assay - |
| Quality Level 100 | Quality Level 100 | Quality Level - | Quality Level - |
| storage temp. 2-8°C | storage temp. 2-8°C | storage temp. 2-8°C | storage temp. −20°C |
| solubility H2O: >10 mg/mL | solubility water: 100 mg/mL | solubility - | solubility - |
| color white | color white | color - | color - |
Storage Class
11 - Combustible Solids
WGK
WGK 2
Flash Point (°F)
Not applicable
Flash Point (°C)
Not applicable
PPE (personal protective equipment)
Eyeshields, Gloves, type N95 (US)
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
-
Is the Pravastatin sodium salt hydrate (Cat No.- P4498) cell permeable?
1 answer-
Helpful?
-